by Clinical Neuropsychologist | Monday, March 18, 2024 | Dementia
Abstract INTRODUCTION Older adults represent the fastest growing segment of the homeless community. Little is known about the prevalence of dementia and mild cognitive impairment (MCI) in this population. METHODS Dementia and MCI screening using the Montreal Cognitive...
by Clinical Neuropsychologist | Monday, March 18, 2024 | Dementia
Abstract INTRODUCTION This study investigates the relationship between microglia inflammation in the hippocampus, brain pathologies, and cognitive decline. METHODS Participants underwent annual clinical evaluations and agreed to brain donation. Neuropathologic...
by Clinical Neuropsychologist | Saturday, March 16, 2024 | Dementia
Abstract BACKGROUND With the availability of disease-modifying therapies for Alzheimer’s disease (AD), it is important for clinicians to have tests to aid in AD diagnosis, especially when the presence of amyloid pathology is a criterion for receiving treatment....
by Clinical Neuropsychologist | Friday, March 15, 2024 | Dementia
Abstract INTRODUCTION In 2013, the ALzheimer’s and FAmilies (ALFA) project was established to investigate pathophysiological changes in preclinical Alzheimer’s disease (AD), and to foster research on early detection and preventive interventions. METHODS We...
by Clinical Neuropsychologist | Friday, March 15, 2024 | Dementia
Abstract INTRODUCTION Neuroinflammation is a major contributor to the progression of frontotemporal dementia (FTD). Galectin-3 (Gal-3), a microglial activation regulator, holds promise as a therapeutic target and potential biomarker. Our study aimed to investigate...
by Clinical Neuropsychologist | Friday, March 15, 2024 | Dementia
Abstract INTRODUCTION Neuronal nuclei are normally smoothly surfaced. In Alzheimer’s disease (AD) and other tauopathies, though, they often develop invaginations. We investigated mechanisms and functional consequences of neuronal nuclear invagination in...
